You are here

  • Home
  • Archive
  • Volume 26, Issue 9
  • Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial

Article metrics

Article menu
Download PDFPDF
Ovarian Cancer
Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer: Exploratory Analysis of the Phase II PRECEDENT Trial

 

Online download statistics by month:

Online download statistics by month: February 2019 to March 2023

AbstractFullPdf
Feb 2019600
Mar 20194601
Apr 20191800
May 20192401
Jun 20193001
Jul 20194800
Aug 20191800
Sep 20194302
Oct 20192000
Nov 20193300
Dec 20191600
Jan 20203400
Feb 20201400
Mar 20201900
Apr 20207002
May 20202900
Jun 20202101
Jul 20203200
Aug 20201400
Sep 20202500
Oct 20201500
Nov 20201700
Dec 20202200
Jan 20212400
Feb 20212800
Mar 20213101
Apr 20211700
Jul 2021100
Sep 20211002
Oct 20212400
Nov 2021600
Dec 20212000
Jan 20222600
Feb 20222200
Mar 20225000
Apr 20222000
May 20224800
Jun 20227502
Jul 20224001
Aug 20225401
Sep 20225901
Oct 20225100
Nov 20224000
Dec 20224600
Jan 20233300
Feb 20238602
Mar 20234301
Total1468019